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Abstract
Background: We previously reported the anti-angiogenic activity of paeonol isolated from Moutan Cortex. In the present
study, we investigated the negative effect of paeonol oxime (PO, a paeonol derivative) on basic fibroblast growth factor
(bFGF)-mediated angiogenesis in human umbilical vein endothelial cells (HUVECs) (including tumor angiogenesis) and pro-
survival activity in HT-1080 fibrosarcoma cell line.
Methodology/Principal Findings: We showed that PO (IC50 =17.3 mg/ml) significantly inhibited bFGF-induced cell
proliferation, which was achieved with higher concentrations of paeonol (IC50 over 200 mg). The treatment with PO blocked
bFGF-stimulated migration and in vitro capillary differentiation (tube formation) in a dose-dependent manner. Furthermore,
PO was able to disrupt neovascularization in vivo. Interestingly, PO (25 mg/ml) decreased the cell viability of HT-1080
fibrosarcoma cells but not that of HUVECs. The treatment with PO at 12.5 mg/ml reduced the levels of phosphorylated AKT
and VEGF expression (intracellular and extracelluar) in HT-1080 cells. Consistently, immunefluorescence imaging analysis
revealed that PO treatment attenuated AKT phosphorylation in HT-1080 cells.
Conclusions/Significance: Taken together, these results suggest that PO inhibits bFGF-induced angiogenesis in HUVECs
and decreased the levels of PI3K, phospho-AKT and VEGF in HT-1080 cells.
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Introduction
Angiogenesis in embryonic development, reproduction and
wound healing is tightly regulated by the balance between the
angiogenic inhibitors and activators [1,2,3,4]. The obligatory
dependence of solid tumor growth and progression on angiogen-
esis are well supported and accepted [5]. Basic fibroblast growth
factor (bFGF) and vascular endothelial growth factor (VEGF) have
been well documented as angiogenic activators [6,7,8]. While
VEGF is a primary mediator of angiogenic responses, bFGF is also
one of potent angiogenesis inducers to stimulate the vascular
endothelial mitogenesis and is often involved in pathologic
angiogenesis. bFGF is routinely employed as angiogenic polypep-
tide for experimental studies [9].
Tumor angiogenesis involves complex and multiple vascular
endothelial responses as well as contributions from tumor cells.
The endothelial responses include angiogenic factor-stimulated
changes in the vascular endothelial permeability, degradation of
the basement membrane by metalloproteases, migration, remod-
eling and proliferation of endothelial cells to form capillary tubes,
and other processes. On the other hand, tumor cells or host
stromal cells express VEGF induced by hypoxia and other
autocrine or paracrine growth factors [2,3,4,6,7,8,9] to stimulate
endothelial progenitor cells for angiogenesis. Interruptions of one
or more steps in these processes can negatively affect angiogenesis
and inhibit early malignant lesions to lower the cancer risk [10]
VEGF expression is mediated by the phosphoinositide 3-kinase
(PI3K) pathway in endothelial cells [11]. Also, PI3K pathway
reveals its effects through its downstream kinase AKT to regulate
various cellular processes including angiogenesis [12].
Paeonol oxime (1-[2-hydroxy-4-methoxy phenyl] ethanone
oxime; PO) was derived from paeonol (2-hydroxy, 4-methoxy
acetophenone), which has been shown to be anti-angiogenic [13]
(Fig. 1). We designed and synthesized PO so that it also shares
some similarity with acetylsalicylic acid (Fig. 1), a well known anti-
inflammatory pain killer but also with anti-angiogenic activity
[1,14], with the goal to achieve better solubility and anti-
angiogenic potency than paeonol. In this regard, we tested the
anti-angiogenic properties of PO on bFGF-stimulated human
umbilical vein endothelial cells (HUVECs) by examining prolifer-
ation, migration, tube formation and chick chorioallantoic
membrane (CAM). We also explored the potential signaling
events affected by PO in angiogenic HT-1080 cells by Western
blotting and immunofluorescence microscopy.
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PO inhibited bFGF-induced proliferation of HUVECs
The cytotoxicity of PO against non-proliferating HUVECs
(absence of angiogenic factors) was first tested to define the range
of non-toxic concentrations of PO for in vitro angiogenesis
experiments. As shown in Fig. 2A, after 24 h incubation, PO
decreased MTT metabolizing ability (metabolic viability) of
HUVECs in a concentration-dependent manner, with less than
20%decrease at up to 50 mg/ml of PO.Allsubsequent angiogenesis
experiments were carried out at even lower concentrations (6.25,
12.5 or25 mg/ml)tomake sureofabsenceofsignificantcelldeathin
the assays. Consistent with the results of cytotoxicity assay, 5-
bromo-29-deoxyuridine (BrdU) proliferation assay further con-
firmed non-toxic effect of PO in HUVECs (Fig. 2B).
Since angiogenic factor-stimulated endothelial cell proliferation
is a key step of the angiogenic processes [7], the effect of PO on
bFGF (10 ng/ml) induced mitogenic response in HUVECs at non-
toxic concentrations was analyzed. PO significantly inhibited
bFGF-induced proliferation of HUVECs with IC50 of 17.3 mg/ml
(Fig. 2C). In comparison, the parental compound paeonol
Figure 1. Chemical structure of paeonol oxime. Paeonol oxime
(PO) (1-[2-hydroxy-4-methoxy phenyl] ethanone oxime) was synthe-
sized from paeonol.
doi:10.1371/journal.pone.0012358.g001
Figure 2. PO inhibits bFGF-induced proliferation of HUVECs. (A) Cytotoxic effect of PO in HUVECs. Cells (5610
3 cells/well) were seeded onto
0.1% gelatin-coated 96-well plates, starved for 6 h in M199 containing 5% heat-inactivated FBS and treated with various concentrations of PO (0,
6.125, 12.5, 25 or 50 mg/ml) for 24 h. Cell viability was measured by MTT assay. (B) Effect of PO on the proliferation of HUVECs. Cells (3610
3 cells/well)
were treated with various concentrations of PO (0, 6.125, 12.5, 25 or 50 mg/ml) for 48 h. (C) Effect of PO on the proliferation of bFGF treated HUVECs.
Cells (3610
3 cells/well) were treated with various concentrations of PO (0, 6.125, 12.5, 25 or 50 mg/ml) in the absence or presence of bFGF (10 ng/ml)
for 48 h. (D) Effect of paeonol on the proliferation of bFGF treated HUVECs. Cells (3610
3 cells/well) were treated with various concentrations of
paeonol (0, 25, 50, 100 or 200 mg/ml) in the absence or presence of bFGF (10 ng/ml) for 48 h. Cell proliferation assay was performed using a 5-bromo-
29-deoxyuridine (BrdU) colorimetric assay kit. The statistically significant differences between control and PO treated groups were calculated by the
Student’s t-test.
*,p ,0.05 and
***,p ,0.001 versus control.
doi:10.1371/journal.pone.0012358.g002
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expected to be over 200 mg/ml (Fig. 2D). The marked difference
observed here between PO and paeonol rendered further
evaluation of the impact of PO on more of the endothelial
responses induced by bFGF.
PO inhibited bFGF-induced migration and tube
formation of HUVECs
To explore the effects of PO on bFGF-stimulated angiogenesis, the
migration assay using the Boyden chamber was performed. As shown
in Fig. 3A, cell motility of HUVECs was increased by 10.9-fold after
bFGFtreatment as compared with untreated control.In contrast, PO
significantly inhibited bFGF-induced migration of HUVECs, in a
concentration-dependent manner with IC50 of 5.3 mg/ml.
It is known that HUVECs undergo extensive in vitro differentiation
to form capillary-like tubes on the Matrigel and bFGF stimulates this
process [5]. In our experiments, PO significantly inhibited bFGF-
induced tube formation by HUVECs, with IC50 of 6.2 mg/ml
(Fig. 3B). Together, these data demonstrated that PO was able to
inhibit critical processes involved in angiogenic responses.
PO disrupted bFGF-induced angiogenesis in CAM assay
To confirm the anti-angiogenic potential of PO, chick CAM
assay was employed in the physiological context of vascular
Figure 3. PO inhibits bFGF-induced migration and tube formation of HUVECs. Cell migration through gelatin-coated filters was measured
by using the Boyden chamber. HUVECs (5610
4 cells/well) were plated into the upper chamber with or without various concentrations of PO and
incubated for 6 h at 37uC in a 5% CO2 incubator. Cells migrated to the lower surface were photographed randomly under an Axiovert S 100 light
microscope at6100 magnification and counted. (B) Tube formation assay was performed using growth factor reduced Matrigel. Cells were fixed with
Diff-Quick solution, photographed randomly under an Axiovert S 100 light microscope at6100 magnification and counted. All data were expressed
as mean 6 S.D. The statistically significant differences between control and PO treated groups were calculated by the Student’s t-test.
###,p ,0.001
versus untreated control.
*,p ,0.05 and
**,p ,0.01 versus bFGF control.
doi:10.1371/journal.pone.0012358.g003
PO Inhibits Tumor Angiogenesis
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12358endothelial cells within intact vessels. As shown in Fig. 4, the
treatment with bFGF (100 ng/embryo) resulted in a 2.6-fold
increase of new blood vessels under the thermonox disc applied on
the CAMs. Furthermore, PO treatment at both doses of 0.25 and
0.5 mg/egg almost totally nullified bFGF-induced angiogenesis
without apparent thrombosis and hemorrhage.
PO downregulated the expression of VEGF and PI3K/AKT
signaling in HT-1080 cells
The effect of PO on human HT-1080 fibrosarcoma cells (a
highly angiogenic cancer cell line) was investigated. Interestingly,
PO, at 20 mg/ml, induced apparent cytotoxicity in the HT-1080
fibrosarcoma cells but not in normal mouse embryonic fibroblasts
(MEF) (Fig. 5A). This decrease in cell viability upon PO treatment
was also concentration dependent (Fig. 5A). Since 20 mg/ml PO
did not induce apparent cytotoxicity in non-proliferating HU-
VECs either (Fig. 2A), the result suggests that besides roles in
angiogenesis, PO at certain concentration might selectively affect
viability of certain tumor cells.
Since VEGF is a crucial mediator of angiogenesis, we examined
whether PO affects the expression of VEGF in HT-1080 cells. PO
at 12.5 mg/ml significantly reduced not only the level of the
secretion (Fig. 5B) its but also the expression of VEGF (Fig. 5C).
PI3K/AKT pathway is known to play a crucial role in
angiogenic responses [15,16]. Thus, we examined the potential
role of PO on activation of PI3K and AKT in HT-1080 cells. As
shown in Fig. 5C, PO at 12.5 mg/ml led to the decreased
expression of PI3K and phosphorylation of its downstream target
AKT. In order to confirm the ability of PO to inhibit PI3K/AKT
pathway, a PI3K inhibitor LY294002 was also used as a positive
control for inhibiting PI3K/AKT signaling in HT-1080 cells. As
expected, LY294002 significantly suppressed AKT phosphoryla-
tion and VEGF expression similar to PO treatment (Fig. 5D). This
was further verified by the immunofluorescence microscopy of
HT-1080 cells in presence and absence of LY294002 and PO
treatment (Fig. 5E).
To further confirm that the effects of PO on HT-1080 cells
are due to its action on angiogenic properties, in vitro tube
formation assay was carried out in the cells with or without the
treatment with PO for 24 h (Fig. 6). The culture medium (CM)
from HT-1080 cells induced HUVECt u b ef o r m a t i o nc o m p a r e d
with that from untreated control cells (lanes 1 and 4). In
c o n t r a s t ,l e s st h a nh a l fo fP O - t r e a t e dc e l l sg r o w ni nC M( .47%)
were able to induce HUVEC tube formation, than that cultured
in CM alone (lanes 4 and 5), suggesting that PO is a potent anti-
angiogenic agent. LY294002 was also prevented the tube
formation (lane 6). VEGF and bFGF served as positive controls
(lanes 2 and 3). However, PO had no significant effect on HT-
1080 mediated cell proliferation and VEGF secretion in
HUVECs (data not shown).
Figure 4. PO disrupts bFGF-induced angiogenesis in vivo. PO and bFGF were loaded on CAMs of 10-day-old fertilized chicken eggs. After 72 h
incubation, a fat emulsion was injected into the CAMs for better visualization of the blood vessels. Thermanox disc and surrounding CAMs were
photographed. (A) Untreated control, (B) bFGF-treated control, (C) 0.25 mg of PO with bFGF, and (D) 0.5 mg of PO with bFGF. (E) The number of newly
formed blood vessels per field was counted. All data are presented as mean 6 S.D., n=5. Statistically significant differences between control and
sample groups were calculated by Student’s t-test.
##,p ,0.05 versus untreated control.
*,p ,0.05 and
***,p ,0.001 versus bFGF control.
doi:10.1371/journal.pone.0012358.g004
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Paeonol was reported to have multi-biological activities such as
anti-inflammatory [17,18], anti-allergic [19], anti-tumor [20],
anti-angiogenic [13] and anti-oxidant [21,22] activities. In the
present study, PO was synthesized from paeonol with an
anticipation of improved solubility and increased anti-angiogenic
potential based on the similarity of PO to aspirin. Assays based on
HUVECs clearly demonstrated the improved anti-proliferative
activity of PO compared with paeonol. Specifically, PO inhibited
bFGF-induced proliferation of HUVECs with IC50 of 17.3 mg/ml,
indicating that PO is more potent to inhibit cell proliferation than
paeonol (IC50 .200 mg/ml). Also, PO suppressed HUVEC
motility and tube formation in a concentration dependent manner
and with similar potency (i.e., IC50=6.2 mg/ml). Consistently, PO
significantly disrupted the neovascularization in bFGF-treated
CAM of developing embryos in vivo. Furthermore, PO was
effective at dosage of 0.25 and 0.5 mg per egg, more sensitive than
paeonol, which was effective at 0.8 and 1.6 mg per egg.
Interestingly, PO displayed cytotoxicity against HT-1080 cells
more effectively than HUVECs and MEFs, indicating a possible
selectivity of PO to kill tumor cells over normal cells. It is possible
that the cytotoxicity of PO against HT-1080 observed in Fig. 5A
could also be due to/associated with the inhibition of PI3K/AKT
signaling (Fig. 5D). In future, we plan to further study more of this
interesting phenomenon and what it might implicate in potential
clinical interventions. In terms of the molecular mechanisms
responsible for anti-angiogenic response, VEGF production
promotes the carcinogenic progression of cancer cells [23,24],
and VEGF is an important cytokine involved in both vasculogen-
esis and angiogenesis [25]. We observed that PO inhibited
extracellular production and intracellular expression of VEGF in
HT-1080 cells. These suggest PO would be able to suppress
angiogenic processes in HT-1080 cancer cells as well as in human
endothelial cells, especially considering that it has been reported
that HT-1080 cell-secreted VEGF, promoted the basement
membrane degradation, migration, proliferation and tube forma-
tion of endothelial cells [26], although we have not explored
further on this due to our focus of study on HUVEC angiogenesis
in this report. In other words, the downregulation of VEGF
signaling by PO observed in HT-1080 cells is likely to lead to
inhibition on angiogenesis of fibrosarcoma.
PI3K/AKT pathway has been known to stimulate angiogenesis
[27,28]. Arbiser et al. reported that Solenopsin, the alkaloidal
component of the fire ant, prevented angiogenesis by inhibiting the
activation of PI3K and the phosphorylation of AKT [29].
Nakashio et al. also reported that Topotecan inhibits VEGF-
and bFGF-induced vascular endothelial cell migration via
downregulation of the PI3K-AKT signaling pathway [30].
Similarly, we also showed that PO reduced the expression of
PI3K, subsequently downregulated the phosphorylation of AKT,
and VEGF secretion in HT-1080 sarcoma cells. A PI3K inhibitor
LY294002 significantly suppressed AKT phosphorylation and
VEGF expression, which is similar to PO treatment, implying that
PI3K is related to and downstream of VEGF in the cells.
Furthermore, the results from in vitro capillary tube formation
assay, indicated that PO is able to inhibit HT-1080-mediated tube
formation. Since LY294002 also had a similar inhibitory effect on
tube formation in the same cells, it suggests that PO exerts its anti-
angiogenic activity, possibly via VEGF/PI3KAKT pathway.
Further studies are under way to examine whether PO-mediated
anti-angiogenic activity is associated with this signaling pathway in
HUVEC and cancer cells.
In summary, we demonstrated that PO inhibited bFGF-
stimulated proliferation, migration, tube formation in human
endothelial cells and also disrupted in vivo neovascularization. We
also showed that PO suppressed PI3K/AKT signaling and
reduced VEGF secretion and expression fibrosarcoma HT-1080
cells, which is consistent with the current understanding of the role
of VEGF/PI3K in angiogenesis. The results from tube formation
assay further indicate the anti-tumor angiogenic effect of PO.
Based on our study, PO appears to be a promising angiogenic
inhibitor and applicable to angiogenesis related diseases. Our data
also suggested that PI3K is an intracellular target of PO to for
achieving its inhibition on angiogenesis.
Materials and Methods
Paeonol oxime
Paeonol oxime (1-[2-hydroxy-4-methoxy phenyl] ethanone
oxime, PO; molecular weight: 213) was synthesized from paeonol
(Fig. 1A). Paeonol, hydroxyl ammonium and pyridine in anhydrous
ethanol were stirred for 24 h under reflux and the reaction mixture
was concentrated by Rotary evaporator. The resulting residue was
purified by column chromatography. PO was more soluble as
compared with paeonol due to the extra hydroxyl radical.
Cell culture
Human HT-1080 fibrosarcoma cells (ATCC CCL-121) were
purchased from ATCC (Rockville, MD). The cells were cultured
in RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and 100 units/ml of antibiotic-antimycotics.
HUVECs were isolated from fresh human umbilical cord veins
according to a published protocol [31] and cultured in M199
supplemented with 20% heat-inactivated FBS, 3 ng/ml bFGF, 5
units/ml heparin and 100 units/ml antibiotic-antimycotic in 0.1%
gelatin coated flasks. HUVECs were used in passages three to six.
Cytotoxicity assay
MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] assay was performed to determine the cytotoxicity of paenol
oxime against non-proliferative HUVECs, mouse embryonic
fibroblast (MEF) and HT-1080 cells [2]. Briefly, cells were seeded
into 96-well plates at a density of 1610
4 cells per well, grown in
presence of various concentrations (0 ,120 mg/ml) of PO for
24 h. MTT solution (1 mg/ml) was added to each well and
incubated at 37uC for 4 h. The medium was removed, and
formazan formed was solubilized with DMSO and the absorbance
at 570 nm measured by a microplate reader (Molecular Devices
Co., Sunnyvale, CA). The percentage of viable cells was estimated
compared with untreated control.
Figure 5. PO downregulates the expression of VEGF and the PI3K/AKT signaling in HT-1080 cells. (A) HT-1080 cells were treated with PO
for 24 h and the cell viability was assessed by MTT assay. (B) The conditioned medium from HT-1080 cells treated with or without PO for 24 h was
used for VEGF measurement using an ELISA kit. Level of VEGF was normalized to the cell number of each sample after 24 h of PO treatment.
***,
p,0.001 versus control. (C) HT-1080 cells were treated with PO (0, 6.25 or 12.5 mg/ml) for 24 h. The levels of VEGF, PI3K, phospho-AKT and AKT were
determined by Western blotting. (D) HT-1080 cells were treated with LY294002 or PO for 24 h and subjected to Western blotting for VEGF, phospho-
AKT and AKT. (E) Cells were treated with LY294002 or PO as described in (D) and incubated with anti-phospho-AKT and FITC conjugated secondary
antibodies. The immunostained cells were mounted in medium containing DAPI and visualized under a Carl Zeiss LSM5 confocal microscope.
doi:10.1371/journal.pone.0012358.g005
PO Inhibits Tumor Angiogenesis
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12358Proliferation assay
Cell proliferation assay was performed using a 5-bromo-29-
deoxyuridine (BrdU) colorimetric assay kit according to the
manufacturer’s instructions. HUVECs (3610
3 cells/well) were
seeded into 0.1% gelatin-coated 96-well plates and incubated
in a humidified incubator for 24 h. Cells were starved for 6 h
in M199 containing 5% heat-inactivated FBS and then treated
with various concentrations of PO or paeonol in the absence or
presence of bFGF (10 ng/ml) in M199 containing 5% heat-
inactivated FBS and 5 units/ml heparin at 37uC for 48 h. Cells
were added with BrdU for additional 6 h, fixed with FixDenat
solution for 30 min and incubated with anti-BrdU followed
by the horseradish peroxidase reaction. The reaction was
terminated by addition of 25 mlo f1 MH 2SO4 and the
absorbance was measured using a microplate reader (Molec-
ular Devices Co., Sunnyvale, CA) at 450 nm–690 nm. IC50
of PO paeonol was calculated with GraphPad Prism 5.0
software.
Figure 6. PO inhibits the tube formation of HUVECs induced by culture supernatants of HT-1080 cells. Tube formation assay was
performed using growth factor reduced Matrigel. (A) Cells were fixed with Diff-Quick solution and photographed randomly under an Axiovert S 100
light microscope at6100 magnification. (B) Tube networks were quantified using NIH Scion image program. All data were expressed as mean 6 S.D.
The statistically significant differences between control and PO treated groups were calculated by the Student’s t-test.
###,p ,0.001 versus untreated
control in M199 medium.
***,p ,0.001 versus culture supernatant from HT-1080.
doi:10.1371/journal.pone.0012358.g006
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The motility of HUVECs to pass through gelatin-coated filters
was measured by using the Boyden chamber (Nuero Probe, Inc.,
Cabin John, MD). Briefly, polyester membrane (12 mm pores) was
coated with 0.1% gelatin for 30 min and dried. The lower
chamber was filled with 30 ml of M199 containing 0.5% BSA in
the presence or absence of bFGF (10 ng/ml). The coated
membrane and upper chamber were laid over the lower chamber.
HUVECs (5610
4 cells/well) were plated onto the upper chamber
with or without various concentrations of PO and incubated for
6 h at 37uC in a 5% CO2 incubator. After incubation, the
membrane was fixed with Diff-Quick fixative and stained with
Diff-Quick Solution I and II (DADE Behring Inc., Newark, DE).
The magnitude of the migrated cells was evaluated by counting
the migrated cells in 2 random high-power (6100) microscope
fields per well under an Axiovert S 100 light microscope (Carl
Zeiss Inc., Weimar, Germany) at 6100 magnification.
In vitro tube formation assay
Tube formation assay was performed using growth factor
reduced Matrigel as previously described [3,4,32]. HUVECs
(7610
4 cells) were seeded onto growth factor reduced Matrigel-
coated 24-well plates and treated with or without various
concentrations of PO in M199 with 1% FBS, 10 ng/ml bFGF
and 5 units/ml heparin for 24 h at 37uC, or culture medium (CM)
from HT-1080 cells treated with or without PO treatment. The
cells were fixed with Diff-Quick solution and visualized under an
Axiovert S 100 light microscope (Carl Zeiss Inc., Weimar,
Germany) in 3 random high-power (6100) microscope fields per
well. The number of circular tubules was counted by using Image-
ProH Plus 4.5 (Media CyberMetics Inc., Bethesda, MD) software.
Chick chorioallantoic membrane (CAM) assay
In vivo anti-angiogenic activity of PO was assessed using CAM
assay as described previously [32]. Briefly, PO and bFGF (100 ng)
were loaded onto a 1/4 piece of thermonox disc (Nunc,
Naperville, IL). The dried thermonox disc was applied to the
CAM of a 9-day-old embryo and incubated for 48 h. Then fat
emulsion was injected under the CAM for better visualization of
the blood vessels. The number of newly formed blood vessels was
counted. The experiment was repeated twice with 15 eggs per
group.
Enzyme linked immunosorbent assay (ELISA) for VEGF
ELISA was performed using Biosource Human Vascular
Endothelial Growth Factor ELISA kit (Biosource International
Inc., Camarillo, CA), following manufacturers’ instructions. The
minimum detectable dose of VEGF is ,5 pg/ml, and 100% cross-
reactivity with human VEGF-121 and complete parallelism with
human VEGF-165. Percentages of coefficient of variation CV) in
intra- and inter-assay were 3.7–5.5% and 6.5–9.3%, respectively.
All samples were within the dynamic range of the standard curve.
Western blot analysis
Cell lysate preparation and immunoblotting were as described
previously [3,32]. In brief, HT-1080 cells were lyzed in lysis buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton
X-100, 0.1% SDS, 1 mM EDTA, supplemented with protease
inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml
pepstatin A, and 1 mM of 4-(2-aminoethyl) benzenesulfonyl
fluoride) and phosphatase inhibitors (1 mM NaF and 1 mM
Na3VO4). The extracts were incubated on ice for 20 min,
centrifuged at 140006 g for 20 min at 4uC and supernatants
were collected. Protein conntraions were determined by Bradford
assay (Bio-Rad), and proteins were separated by electrophoresison
SDS-polyacrylamide gels and transferred to Hybond-C nitrocel-
lulose membranes at 300 mA for 2 h. Membranes were blocked
with 5% nonfat dry milk in TBS-T (0.05% Tween-20, 138 mM
NaCl, and 25 mM Tris base). Protein expression was determined
using antibodies against VEGF (Santa Cruz Biotechnologies,
Santa Cruz, CA), P13K, phospho-AKT, AKT (Cell Signaling
Technology, Danvers, MA) and b-actin (Sigma, St. Louis, MO).
The blots were incubated with horseradish peroxidase-conjugated
antibodies and detected by enhanced chemiluminescence (ECL)
detection system.
Immunofluorescence microscopy
HT-1080 cells were fixed on poly-L-lysine coated slides in 4%
paraformaldehyde and then permeabilized in cold methanol. Cells
were then incubated with 10% normal goat serum in PBS for 1 h,
followed by immunostaining with rabbit polyclonal phospho-AKT
antibody (Cell Signaling Technology, Danvers, MA). Rabbit IgG
fluorescein isothiocyanate (FITC) antibody H & L (Abcam,
Cambridge, MA) was used as the secondary antibody. The
immunostained cells were mounted in medium containing DAPI
(Vectashield, Vector Labs, Burlingame, CA) and visualized under
a Carl Zeiss LSM5 confocal microscope.
Statistical analysis
All data were presented as mean 6 standard deviation (S.D.).
The statistically significant differences between control and PO
treated groups were calculated by Student’s t-test.
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